Idexx Laboratories (IDXX) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $274.6 million.
- Idexx Laboratories' Income from Continuing Operations rose 1793.89% to $274.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1860.76%. This contributed to the annual value of $887.9 million for FY2024, which is 506.78% up from last year.
- As of Q3 2025, Idexx Laboratories' Income from Continuing Operations stood at $274.6 million, which was up 1793.89% from $294.0 million recorded in Q2 2025.
- Idexx Laboratories' Income from Continuing Operations' 5-year high stood at $294.0 million during Q2 2025, with a 5-year trough of $132.0 million in Q2 2022.
- Over the past 5 years, Idexx Laboratories' median Income from Continuing Operations value was $204.3 million (recorded in 2021), while the average stood at $208.8 million.
- As far as peak fluctuations go, Idexx Laboratories' Income from Continuing Operations skyrocketed by 8263.57% in 2021, and later tumbled by 3485.93% in 2022.
- Idexx Laboratories' Income from Continuing Operations (Quarter) stood at $162.8 million in 2021, then increased by 5.8% to $172.2 million in 2022, then grew by 12.96% to $194.5 million in 2023, then increased by 11.12% to $216.1 million in 2024, then increased by 27.05% to $274.6 million in 2025.
- Its Income from Continuing Operations stands at $274.6 million for Q3 2025, versus $294.0 million for Q2 2025 and $242.7 million for Q1 2025.